ArticleDigestive diseases and sciences2004
Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress.
Article in Digestive diseases and sciences, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 39 citations in OpenAlex.
- The interaction of bile acids and gut inflammation influences the pathogenesis of inflammatory bowel disease.Internal and emergency medicine · 2023Review
- Effects of hemicellulose on intestinal mucosal barrier integrity, gut microbiota, and metabolomics in a mouse model of type 2 diabetes mellitus.Frontiers in microbiology · 2023Article
- Bile acids as inflammatory mediators and modulators of intestinal permeability.Frontiers in immunology · 2022Review
- High-Fat, Western-Style Diet, Systemic Inflammation, and Gut Microbiota: A Narrative Review.Cells · 2021Review
- Current knowledge on non-steroidal anti-inflammatory drug-induced small-bowel damage: a comprehensive review.Journal of gastroenterology · 2020Review
- Negative Effects of a High-Fat Diet on Intestinal Permeability: A Review.Advances in nutrition (Bethesda, Md.) · 2020Review
- Ursodeoxycholic acid attenuates 5-fluorouracil-induced mucositis in a rat model.Oncology letters · 2018Article
- Ursodeoxycholic acid protects against intestinal barrier breakdown by promoting enterocyte migration via EGFR- and COX-2-dependent mechanisms.American journal of physiology. Gastrointestinal and liver physiology · 2018Article
- Three measurable and modifiable enteric microbial biotransformations relevant to cancer prevention and treatment.Global advances in health and medicine · 2014Review
- High-fat-induced intestinal permeability dysfunction associated with altered fecal bile acids.World journal of gastroenterology · 2012Article
- Intestinal bile acid physiology and pathophysiology.World journal of gastroenterology · 2008Review
- Protective effect of octreotide and infliximab in an experimental model of indomethacin-induced inflammatory bowel disease.Digestive diseases and sciences · 2008Article
- Heat stress increases protein antigen transport across the intestinal epithelium via a mechanism of impairing proteolytic enzymatic activity.Digestive diseases and sciences · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the effect of ursodeoxycholic acid (UDCA) on intestinal permeability (IP) and reactive oxygen species (ROS) generation in indomethacin-induced enteropathy, a well-known experimental model of Crohn's disease. Seventy-eight male Wistar rats were randomly assigned to receive indomethacin, indomethacin + UDCA, or vehicles. Indomethacin induced a significant increase in the fraction of urinary excretion of 51Cr-EDTA following oral administration (7.9 +/- 1.3 vs 2.3 +/- 0.2%; P < 0.05) and lucigenin-amplified chemiluminescence in intestinal fragments ex vivo (10.1 +/- 1.9 vs 2.6 +/- 0.4 cpm x 10(3)/mg; P < 0.05) compared to controls. UDCA significantly reversed these effects (P < 0.05), without being incorporated in biliary bile acid composition (HPLC analysis). These findings support a local protective effect of UDCA in experimental ileitis by the modulation of intestinal barrier dysfunction and oxidative stress. In short, they provide insights into mechanisms of action of UDCA in intestinal inflammation and a new perspective on the treatment of Crohn's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.